is a privately funded drug discovery company focusing on the development of a high-throughput 3D screening platform for heart failure and cardiomyopathies. We employ the world-wide first, self-organizing cardiac organoids (Cardioids) that recapitulate the physiology of human heart chambers in an unprecedented way. This Cardioid-based screening platform has the potential to radically change the current cardiovascular drug discovery paradigm, leading to higher success rates in clinical trials while reducing cost and time of compound development.